Purpose
Mitotic spindle tissue protein 2A(MZT2A) has the properties of the core subunit of the γ-tubulin ring complex ( γ-TuRC ) and is involved in mediating the formation of bipolar spindles in mitosis. The lack of MZT2A will weaken the nucleation activity of microtubule ( MT ) and slow down the rate of cell proliferation. Although there is evidence that the expression of MZT2A plays a crucial role in the development of some tumors, there is still no research on MZT2A in pan-cancer. Therefore, we aim to explore the prognostic value of MZT2A in a variety of cancer types and to study its potential immune function.
Methods
This study was conducted with datasets from The Cancer Genome Atlas, the Cancer Cell Lineage Encyclopedia, Genotype Tissue Expression and the Human Protein Atlas. Bioinformatic methods were used to analyse the correlation between MZT2A expression levels in different tumours and survival prognosis, immune infiltration, immune checkpoint genes, immune regulatory genes, tumour mutational load (TMB), tumour neoantigens, homologous recombination defects (HRD), microsatellite instability (MSI), tumour stemness score and enrichment analysis regarding MZT2A.
Results
MZT2A was highly expressed in most tumours and was positively or negatively correlated with the prognosis of patients with different tumours. MZT2A was also found to be negatively correlated with the immune microenvironment, immune infiltrating cells, and immune-related genes in most tumours, and was strongly correlated with TMB in 11 tumours, MSI in 10 tumours, tumour neoantigens in 5 tumours, and HRD in 12 tumours, and MZT2A expression was significantly correlated with RNA stemness score (RNAss) in 24 tumours and DNA stemness score (DNAss) in 12 tumours. The results suggest that MZT2A can be used as a target or predictor of tumour therapy. the immunosuppressive effect of MZT2A in TME suggests that anti-MZT2A immunotherapy may be a new direction in cancer treatment.
Conclusion
MZT2A is involved in tumour development and can be used as a prognostic marker for a variety of tumours and as a target or predictor for tumour immunotherapy.